Medicamen Biotech Limited (NSE:MEDICAMEQ)

Market Cap	2.96B -42.2%
Revenue (ttm)	2.01B +19.9%
Net Income	96.41M +35.6%
EPS	7.11 +27.2%
Shares Out	n/a
PE Ratio	30.74
Forward PE	n/a
Dividend	1.00 (0.41%)
Ex-Dividend Date	Sep 19, 2025

Volume	9,678
Open	238.10
Previous Close	237.65
Day's Range	230.10 - 239.05
52-Week Range	212.40 - 447.65
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Medicamen Biotech

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 376
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MEDICAMEQ

Financial Performance

In fiscal year 2026, Medicamen Biotech's revenue was 2.01 billion, an increase of 19.90% compared to the previous year's 1.68 billion. Earnings were 96.41 million, an increase of 35.64%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 14, 2026

Data Sources Report a data error